Company’s lead product candidate shows some benefit for patients with cirrhosis due to fatty liver disease
Akero Therapeutics Inc. shares AKRO, -3.56% fell more than 60% premarket on Tuesday after the company released an update on its lead product candidate, a treatment for nonalcoholic steatohepatitis, a form of fatty liver disease.
Only 22% to 24% of the patients with compensated cirrhosis due to NASH receiving the treatment, efruxifermin, had at least a one-stage improvement in liver fibrosis, the study’s primary endpoint, Akero said in a release. But roughly 60% of patients receiving the treatment had NASH resolution after 36 weeks, compared with 26% for placebo, “representing the highest response rates reported to date for NASH resolution in this patient population,” the company said.
“We set a high bar with the primary endpoint after only 36 weeks of treatment,” Dr. Andrew Cheng, Akero’s president and CEO, said in a statement. But looking at the overall data, including the fibrosis improvement trend and statistically significant rates of NASH resolution, Akero believes efruxifermin “has the potential to show additional improvements for patients after the long-term follow-up period is complete” at week 96, Cheng said.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
After-hours movers: Akero Therapeutics gains ahead of data, PagerDuty falls on conv. offeringAfter-hours movers: Akero Therapeutics gains ahead of data, PagerDuty falls on conv. offering
Read more »
Bristol Myers Squibb to buy cancer drugmaker Mirati Therapeutics in up to $5.8B dealBristol Myers Squibb will buy Mirati Therapeutics in a deal worth up to $5.8 billion, or $58 per share, the biopharmaceutical company announced Sunday.
Read more »
Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 BillionDeal expands pharmaceutical company’s portfolio of cancer drugs
Read more »
Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billionMirati develops commercial-stage oncology therapies, and through the deal, Bristol Myers Squibb will add lung-cancer medicine Krazati, among others, to its...
Read more »
Exxon, Chevron, Mirati, Disney, Lockheed, and More Stock Market MoversExxon and Chevron shares rise after a surge in oil prices following the weekend attack on Israel from Hamas, Mirati Therapeutics stock falls after Bristol...
Read more »
Bristol-Myers Squibb to acquire Mirati in $5.8 billion dealBristol-Myers Squibb (BMY.N) on Sunday said it will acquire Mirati Therapeutics (MRTX.O) in a transaction that values the cancer drugmaker at up to $5.8 billion.
Read more »